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Novas 2-(R-fenil)amino-3-(2-metilpropenil)-[1,4]-naftoquinonas (R = H, 4-OMe, 4-Ferrocenil, 




) derivadas do nor-lapachol [2-hidroxi-3-(2-
metilpropenil)-1,4-naftoquinona] foram obtidas em bons rendimentos. A estrutura dos compostos 
foi proposta com base em estudos de difração de raios-X (R = OMe, 2b), dados de RMN de 1H 
e 13C e cálculos teóricos utilizando o funcional B3LYP e a base 6-311+G(2d,p). Os potenciais de 
meia-onda das aminonaftoquinonas e o deslocamento químico do hidrogênio da cadeia 3-propenil 
dos compostos 2a-k mostraram boa correlação com as constantes de Hammett dos substituintes 
presentes no anel fenileno. A avaliação da citotoxicidade evidenciou atividade antitumoral 
promissora para o substrato metóxi-nor-lapachol 1 e o derivado 4-ferrocenil 2c. 
Novel 2-(R-phenyl)amino-3-(2-methyl-propenyl)-[1,4]-naphthoquinones (R = H, 4-OMe, 




) derived from nor-lapachol 
[2-hydroxy-3-(2-methylpropenyl)-1,4-naphthoquinone] were obtained in good yields. Their 
structures were proposed on the basis of a single crystal X-ray diffraction study (R = OMe, 2b), 
1H and 13C NMR studies and calculations using the B3LYP functional and the 6-311+G(2d,p) 
basis set. The half-wave potentials of the aminonaphthoquinones and 1H NMR chemical shifts of 
the 3-propenyl hydrogen in 2a-k show good correlation with the substituent Hammett constants 
on the phenylamino ring. The antitumor assays showed promising activity for substrate methoxy-
nor-lapachol 1 and the 4-ferrocenyl derivative 2c.
Keywords: Nor-lapachol, arylamine, aminonaphthoquinone, electrochemistry, B3LYP, 
antitumor activity
Introduction
Naphthoquinones are widely distributed in nature and 
some of these molecules have an important role in the 
biochemistry of microbial energy production, by means 
of photosynthesis and respiratory chain.1 Compounds 
containing the quinone group are known for exhibiting 
antitumor,2 trypanocide,3 moluscicide,4 fungicide5 and 
antimalarial6 activities. The presence of an amino group 
in quinones has led to interesting biologically active 
compounds.7-12
Biological activity of quinones is often related to 
their electrochemical behavior.13 The ability to accept 
one or two electrons to form the corresponding radical 
anion (Q•-) or dianion (Q2-) species is believed to induce 
formation of reactive oxygen species, responsible for the 
oxidative stress in cells.14 The electron-accepting capacity 
of naphthoquinones may be tuned by carbonyl position 
changes (1,2- x 1,4-naphthoquinones)15 or different 
substituents or functions attached to the naphthoquinone 
moiety, and the use of electrochemical methods to study 
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this type of molecules has proven to be useful.16,17 We 
reported recently18 the synthesis of a series of 2-arylamino-
1,4-naphthoquinones from 2-methoxy-1,4-naphthoquinone 





p-toluenesulfonic acid as catalysts. The reactions of both 
electron-donor and electron-attracting substituted anilines 
having given good yields of the respective products, we 
decided to investigate the analogous reactions of the 
methoxy-derivatives of nor-lapachol [2-hydroxy-3-(2-
methyl-propenyl)-1,4-naphthoquinone]4 and lapachol 
[2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone].19 
Nor-lapachol is obtained from lapachol by the Hooker 
oxidation20 and has been used as a substrate for the 
synthesis of several active compounds.9-12 The incorporation 
of polyamines to this quinone, for example, has led 
to significant increase in the DNA topoisomerase II-a 
inhibition, compared to the original naphthoquinone.13,14 
Furthermore, arylamino derivatives of nor-a and nor-b 
lapachones present potent antitumor11 and trypanocide 
activities.9
Herein is the first report on the synthesis and 
characterization of the novel 2-arylamine derivatives of nor-
lapachol 2a-k, including 2-(4-ferrocenyl-phenyl)amino-3-
(2-methylpropenyl)-1,4-naphthoquinone 2c (Figure 1) and 
cytotoxic screening against the several cancer cell lines 
(SF-295, HCT-8, MDAMB-435 and HL-60). Because 
correlations between electrochemical potentials and the 
inhibitory activity of naphthoquinones on Epstein-Barr 
virus early antigen activation21 and their cytotoxicity22 has 
been reported, we also investigated the redox properties of 
these compounds by cyclic voltammetry.
Results and Discussion
Syntheses
The compounds 2a-k (Figure 2) were synthesized from 
2-methoxy-3-(2-methylpropenyl)-[1,4]-naphthoquinone 
with various aromatic amines, in the presence of the 





methanol under reflux.18 The products are stable in the solid 
state and in solution. Compounds 2a, 2b were obtained 
in a pure state, whereas 2c-k were purified by column 
chromatography using a mixture of ethyl acetate / hexane 
(1:5) as eluent. They were obtained in yields ranging from 
84 to 73% and formulated on the basis of analytical and 
spectroscopic data (see Experimental).
The 1H NMR and infrared spectra of compounds 2a-k 
are consistent with their composition and structure. The 
1H NMR spectra exhibit signals in the d 7.5-8.2 ppm 
region as double dublets and triple dublets, attributed to 
the four naphthoquinone aromatic hydrogens H5-H8. 
Attributions were made on the basis of 1H x 1H-COSY 
experiments, J values and multiplicity. All expected 
resonances were observed in the 13C NMR spectra of 
compounds 2a-k. The carbonyl peaks appear around d 183 
and 180, and those attributed to C2 bound to the nitrogen 
at about d 145. The other chemical shifts are compatible 
with the structures proposed for these compounds. We 
observed that the chemical shift of H18 (Figure 2) in the 
1H NMR spectra of 2a-k is directly influenced by the 
nature of the R substituent group in the phenylamino ring 
[5.80 (4-OMe) < d
H(18)
 < 6.08 (4-NO
2
)].
X-ray structure / Theoretical calculations 
The structure of 2-(4-methoxy-phenyl)amino-3-(2-
methylpropenyl)-1,4-naphthoquinone 2b was determined 
by a single crystal X-ray diffraction study (Figure 3). The 
average C-C, C-O, C=O and C-N bond lengths are in good 
agreement with the literature.36 The naphthoquinone ring 
system of 2b is approximately planar, the dihedral angle 
between the naphthoquinone plane and the arylamine 
phenyl ring being 47.3°(1). The torsion angles around 
the fragments involved in the H-bond are: C(2)-N(1)-
C(11)-C(12), -158.94(17)o, C(1)-C(2)-N(1)-C(11) 
-154.47(16)o and N(1)-C(2)-C(1)-O(2) -3.2(2)°. The 
planar unsaturated side chain is twisted about 54° with 
respect to the ring system. This is the first reported structure 
of an amine derivative of nor-lapachol. 
The packing of 2b involves molecules that interact 
through classical and non-classical hydrogen bonds, 
forming a 1D infinite network along the crystallographic 
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Figure 2. Compounds 2a-k.
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makes a classical and a non-classical hydrogen bonds with 
H1 to the N1 atom (amino group) and with H12 to the C12 
atom (C11-C16 phenyl ring) of a neighboring molecule, 
forming a six-membered ring [symmetry code: i = x-1, y, z]. 
In addition the other C=O group interacts via O2ii with 
H5 to the C5 forming now a ten-membered ring. For more 
details of the crystal structure, see Supplementary material.
 Starting from the experimental structure of 2b 
(Figure 3), the geometries of 2a-2e and 2h-2i were fully 
optimized with the B3LYP/6-31G(d) method.37 Energies 
and molecular properties were obtained from a single-
point calculation on the optimized geometries using the 
6-311+G(2d,p) basis set38 and the B3LYP functional.39 To 
confirm that the most stable conformation in the gas-phase 
is similar to that found in the solid state the geometry of an 
alternative conformation for 2b, with the 2-methylpropenyl 
group bonded to position 3 of the naphthoquinone ring 
rotated by 180o was also optimized. This alternative 
conformation is 0.4 kcal mol-1 less stable than the solid 
state conformation. The barrier for conversion between 
the two conformers calculated at the 6-31G(d) level is 
5.5 kcal mol-1.
Calculations of the absolute 1H NMR chemical shifts 
using the GIAO approach40 confirmed that electron-
attracting groups yield higher d
H(18)
 values than electron-
donor groups. Calculations including solvent (chloroform) 
show essentially the same behavior. Interestingly, the 
d
H(18)
 value for the alternative conformation with the 
2-methylpropenyl side chain rotated by 180o is shifted 
highfield by 1.67 ppm, compared to the same hydrogen in 
the most stable conformation. The fact that the experimental 
values are intermediate between the calculated values for 
the two conformations suggests that these conformations 
are in equilibrium in solution, although the variable 
temperature 1H NMR spectra of 2a do not show broadening 





Figure 3. View of the ORTEP plot for 2b with labeled atoms and 50% probability ellipsoids.
Figure 4. View of the intramolecular interaction.
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UV-Vis spectra
The UV-Vis spectra of the compounds obtained in CHCl
3
 
show two absorption bands. PBE1PBE/6-311+G(2d,p) 
calculations indicate that the band in the 275-290 nm 
region can be attributed to the aromatic and quinone p-p* 
transitions and the low-energy band in the visible region 
between 456 and 512 nm is attributed predominantly to 
p phenyl-p* naphthoquinone transitions. Electron-donor 
substituents blue shift the latter band, whereas electron-
attracting groups red shift it.
Cyclic voltammetry
The redox behavior of compounds 2a-k was evaluated 





 (0.1 mol L-1). The CVs were obtained 
in the potential range from +1.3 to –2.1V vs FcH/FcH+ as 
internal standard (Table 1). Two quasi-reversible pairs of 
waves were observed for compounds 2a-i in the negative 
region of the CV, which are attributed to the one-electron 
transfer to the naphthoquinone moiety. The redox potentials 
of the naphthoquinone unit are directly influenced by the 
substituents in the phenylamino ring: electron-donor groups 
present lower E
1/2
 when compared to electron-releasing 
groups. The complexity of the CV observed for 2j indicated 
that the nitro group is also electroactive in the cathodic 
region studied41 and because the reduction potentials for the 
nitro and the quinone moieties are similar, we were unable 
to assess the voltammetric parameters for this derivative. 
The data indicate that derivative 2c, R= ferrocenyl (Fc, 
E
1/2
 = -1.23 V) exhibit electronic properties similar to 
compound 2b. This was also observed for the Fc-arylamine 
derivative of lawsone.18
Good correlation of the E
1/2





- Hammett constants42 was obtained (Figures 6 and 7, 
respectively) except for the Fc group (Figure 7) for which 
the low s
p
-  value (-0.03)43 has been correlated to low 
resonance contribution. The linear correlation coefficients 
for both plots suggest that all naphthoquinones of this series 
are reduced by the same mechanism. E
1/2
(1) potentials do 




The antitumor screening of compounds 2a-k was 
carried out against three cancer cell lines: SF-295 (central 
nervous system), HCT-8 (colon), MDAMB-435 (breast) 
through an MTT assay35 and the results, summarized in the 
Figure 5. View of the self-assembly 1D by classical and non-classical hydrogen bonds along the [100] crystallography direction. [Symmetry codes: 
(i) x-1, y, z; (ii) x+1, y, z].
Table 1.  Voltammetric data (V) for 2a-k vs FcH/FcH+ as internal standard
Compound E1/2 (1) E1/2 (2) E1/2 (1) – E1/2 (2) 
2a -1.19 -1.54 0.35
2b -1.23 -1.59 0.36
2c -1.23 - -
2d -1.20 -1.58 0.38
2e -1.23 -1.50 0.27
2f -1.17 -1.57 0.40
2g -1.16 -1.48 0.32
2h -1.10 -1.47 0.37
2i -1.15 -1.53 0.38
2j - - -
2k -1.18 -1.65 0.47
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Supplementary information, show that the Fc-derivative 
2c and the methoxy-substrate 1 presented significant 
proliferation inhibition against MDA-MB435, higher than 
the positive control doxorubicin (DOX). In a second set of 
experiments, four cell lines were used for IC
50
 determination 
of previously selected compounds (1 and 2c). Only methoxy-
nor-lapachol 1 was highly active against MDA-MB435 
and moderately active against HL-60 and HCT-8 cell lines 
(Table 2). The loss of activity of the ferrocenyl derivative 2c 
may be due to decomposition during dilution and defreezing 
of the solution, since this compound is slightly unstable in 
solution in the presence of oxygen. 
Experimental 
Materials and methods 
Reagents and solvents were used without further 
purification. Microanalyses were performed using a Perkin-
Elmer CHN 2400 micro analyser at the Central Analítica, 
Instituto de Química, USP-São Paulo, Brazil. Melting points 
were obtained with a Mel-Temp II, Laboratory Devices-USA 
apparatus and are uncorrected. IR spectra (KBr pellets) 
were recorded on a FT-IR Spectrum One (Perkin Elmer) 
spectrophotometer. 1H and 13C NMR spectra were recorded 
with a Varian Unit Plus 300 MHz spectrometer in CDCl
3
; 
coupling constants are reported in Hertz (Hz) and chemical 
shifts in parts per million (ppm) relative to internal standard 
Me
4
Si. The hydrogen signals were attributed through coupling 
constant values and 1H × 1H - COSY experiments. Electronic 
spectra were taken on a Diode Array 8452A (Hewlett 
Packard-HP) spectrophotometer using spectroscopic grade 
solvents (Tedia Brazil) in 10-3 and 10-4 mol L-1 solutions. 
Cyclic voltammograms were obtained on an Epsilon-BAS 
potentiostat-galvanostat from 1 × 10-3 mol L-1 solutions 
in chloroform containing 0.1 mol L-1 of TBABF
4
 as 
supporting electrolyte, at room temperature and under 
argon atmosphere. A standard three component system was 
used: a carbon-glassy working electrode, a platinum wire 
auxiliary electrode, and an Ag/AgCl reference electrode for 
organic media. Ferrocene was used as an internal standard 
(E
1/2
 0.40 V vs NHE). Density functional calculations 
were carried out using the Gaussian03W molecular orbital 
package.23 Geometries were fully optimized using the 
B3LYP functional24 with the standard 6-31G(d) basis set25 
Solvent effects (chloroform) were estimated by single-point 
calculations on the gas-phase optimized geometries by mean 
of the continuum solvation model using the conductor-like 
polarisable continuum model26 (CPCM) at the same level. 
NMR absolute chemical shifts were calculated using the 
GIAO (Gauge Independent Atomic Orbital) method with the 
B3LYP/6-311+G(2d,p) approach on the B3LYP/6-31G(d) 
optimized geometry. The electronic spectra were calculated 
using the TD (Time Dependent) methodology available 
in Gaussian. The PBE1PBE functional together with the 
6-311+G(2d,p) basis set was employed.
Synthesis of the compounds 2a-k
Compounds 2a-k were synthesized by the same 
procedure we reported recently for the synthesis of 










Table 2. Cytotoxic activity expressed by IC
50
 in μg mL-1 of compounds 
1, 2c and doxorubicin (DOX), with the respective confidence intervals
Compound SF295 HCT-8 MDA-MB435 HL-60
2c > 5 > 5 > 5 > 5
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2-arylamine-1,4-naphthoquinones derived from 2-hydroxy-
1,4-naphthoquinone and were obtained in yields that 
varied from 71% (2c) to 84% (2h).18 [2-methoxy-3-
(2-methylpropenyl)-[1,4]-naphthoquinone] (155 mg, 
0.64 mmol) 1 in MeOH (6.00 mL) was heated under 
reflux in the presence of 4-toluenesulfonic acid (17.2 mg, 




O (20.3 mg, 0.1 mmol) as 
catalysts for 10 min. to dissolve most of 1. After addition 
of the respective arylamine (0.96 mmol), the reactions 
were monitored by TLC (1:9 ethyl acetate/hexane) 
and were stopped when 1 was no more observed. The 
resulting solids were filtered, washed with water and cold 
MeOH and dried under vacuum. The melting points and 
elemental analysis data are indicative of pure compounds. 
In contrast, the analogous reactions of methoxylapachol 
under the same conditions yielded the corresponding 1-aza-
1,2-dihydro-5,10-anthraquinones in low yields described 
previously.19 
2 - ( P h e n y l ) a m i n o - 3 - ( 2 - m e t h y l p ro p e n y l ) - 1 , 4 -
naphthoquinone (2a)







C 79.14; H 5.47; N 4.67%; found: C 79.19; H 5.65; N 
4.62%. 1H NMR (300 MHz, CDCl
3
): d 8.13 (ddd, 1H, 
J 6.51, J 1.51, J 0.49 Hz), 8.10 (ddd, 1H, J 6.51, J 1.51, 
J 0.49 Hz), 7.73 (td, 1H, J 6.51, J 6.51, J 1.51 Hz), 7.65 
(td, 1H, J 6.51, J 6.51, J 1.51 Hz), 7.23 (br t, 1H, J 7.52 
Hz), 7.07 (tt, 1H, J 7.52, J 2.05, J 1.13 Hz), 7.91 (m, 1H), 
6.89 (dt, 1H, J 7.93, J 2.05, J 1.34 Hz), 5.87 (m, 1H), 1.38 
(d, 3H, J 1.54 Hz), 1.24 (d, 3H, J 1.32 Hz). 13C NMR (75 
MHz, CDCl
3
): d 188.2, 184.3, 140.2, 139.5, 137.9, 134.8, 
133.6, 132.6, 130.8, 127.9, 126.7, 124.2, 120.1, 118.9, 
117.0, 100.2, 25.6, 20.6. IR (KBr) ν
max
/cm-1: 3278, 3102, 





290 (log ε 4.15), 463 (3.37). 
2-(4-Methoxy-phenyl)amino-3-(2-methylpropenyl)-1,4-
naphthoquinone (2b)







C 75.66; H 5.74; N 4.20%; found: C 75.56; H 5.69; N 




8.10 (m, 2H), 7.72 
(td, 1H, J 7.49, J 7.49, J 1.54 Hz), 7.63 (td, 1H, J 7.70, J 
1.54 Hz), 5.80 (m, 1H), 6.85 (br d, 2H, J 9.25 Hz), 6.77 
(br d, 2H, J 9.25 Hz), 3.80 (s, 3H), 1.40 (d, 3H, J 1.54 
Hz), 1.25 (d, 3H, J 1.32 Hz). 13C NMR (75 MHz, CDCl
3
): 
183.7, 182.9, 156.5, 140.4, 138.8, 134.4, 133.0, 132.1, 
130.8, 130.4, 126.0, 124.5, 118.4, 115.4, 114.7, 112.9, 
55.4, 25.3, 20.2. IR (KBr) ν
max
/cm-1: 3288, 3100, 3031, 





(log ε 4.20), 511 (3.45). 
2-(4-Ferrocenyl-phenyl)amino-3-(2-methylpropenyl)-1,4-
naphthoquinone (2c)







: C 73.93; H 5.17; N 2.87%; found: C 73.84; 





1H, J 7.40, J 1.57, J 0.51 Hz), 8.13 (ddd, 1H, J 7.40, J 1.57, 
J 0.51 Hz), 7.79 (td, 1H, J 7.40, J 7.40, J 1.57 Hz), 7.69 
(td, 1H, J 7.40, J 7.40, J 0.51 Hz), 7.55 (dd, 2H, J 6.12, J 
2.09 Hz), 7.17 (dd, 2H, J 6.12, J 2.09 Hz), 5.82 (m, 1H), 
4.61 (dd, 2H, J 2.37, J 1.98 Hz), 4.31 (dd, 2H, J 2.37, J 
1.98 Hz), 4.04 (s, 5H), 1.35 (d, 3H, J 1.61 Hz), 1.24 (d, 
3H, J 1.47 Hz). 13C NMR (75 MHz, CDCl
3
): 184.1, 181.8, 
155.8, 139.4, 138.1, 131.7, 133.5, 131.3, 130.2, 129.6, 
125.8, 124.3, 118.2, 114.9, 114.5, 112.3, 69.2, 68.7, 66.3, 
24.9, 19.8. IR (KBr) ν
max
/cm-1: 3281, 3098, 2880, 1670, 





(log ε 4.29), 510 (3.64).
2-(4-Methyl-phenyl)amino-3-(2-methylpropenyl)-1,4-
naphthoquinone (2d)







C 79.47; H 6.03; N 4.41%; found: C 79.43; H 6.01; N 




8.13 (m, 2H), 7.74 
(td, 1H, J 7.57, J 1.47 Hz), 7.66 (td, 1H, J 7.57, J 1.47 
Hz), 7.05 (br d, 2H, J 8.06 Hz), 6.80 (br d, 2H, J 8.06 Hz), 
5.85 (m, 1H), 2.34 (s, 3H), 1.40 (d, 3H J 1.47 Hz), 1.26 (d, 
3H, J 1.22 Hz). 13C NMR (75 MHz, CDCl
3
): 182.1, 181.3, 
157.4, 141.4, 137.5, 133.9, 132.9, 132.0, 131.0, 130.9, 
125.6, 123.9, 119.1, 114.3, 114.1, 112.5, 49.3, 25.1, 20.8. 
IR (KBr) ν
max





/nm: 286 (log ε 4.00), 505 (3.25). 
2-(3-Methyl-phenyl)amino-3-(2-methylpropenyl)-1,4-
naphthoquinone (2e)







C 79.47; H 6.03; N 4.41%; found: C 80.01; H 6.03; N 4.53%. 




8.12 (m, 2H); 7.74 (td, 1H, 
J 7.48, J 7.48, J 1.51 Hz), 7.66 (td, 1H, J 7.48, J 7.48, J 
1.51 Hz), 7.70 (m, 2H); 7.06 (br d, 2H, J 8.30 Hz); 5.84 
(m, 1H); 6.80 (br d, 2H, J 8.30 Hz); 2.34 (s, 3H); 1.40 (d, 
1H, J 1.22 Hz); 1.26 (d, 1H, J 1.33 Hz. 13C NMR (75 MHz, 
CDCl
3
): 181.9, 181.2, 157.3, 141.5, 137.2, 133.8, 133.5, 
132.4, 131.9, 131.0, 130.5, 129.5, 125.3, 123.4, 118.9, 
114.0, 113.8, 112.1, 50.3, 24.5, 20.3. IR (KBr) ν
max
/cm-1: 





/nm: 287 (log ε 4.15), 507 (3.31). 
2-(4-Iodo-phenyl)amino-3-(2-methylpropenyl)-1,4-
naphthoquinone (2f)







C 55.96; H 3.76; N 3.26%; found: C 55.91; H 3.71; N 3.24%. 
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8.13 (dd, 1H, J 7.52, J 1.58 
Hz), 8.10 (dd, 1H, J 7.52, J 1.39 Hz), 7.74 (td, 1H, J 7.52, 
J 7.52, J 1.39 Hz), 7.66 (td, 1H, J 7.52, J 7.52, J 1.58 Hz), 
7.54 (br d, 2H, J 8.71 Hz), 6.65 (br d, 2H, J 8.71 Hz), 5.90 
(m, 1H), 1.47 (d, 3H, J 1.53 Hz), 1.24 (d, 3H, J 1.33 Hz). 
13C NMR (75 MHz, CDCl
3
): 184.3, 183.0, 140.3, 139.8, 
137.7, 136.8, 134.9, 133.4, 132.8, 130.7, 126.5, 124.6, 
118.9, 117.7, 100.3, 87.2, 25.7, 20.8. IR (KBr) ν
max
/cm-1: 





/nm: 290 (log ε 4.01), 460 (3.47). 
2-(3-Iodo-phenyl)amino-3-(2-methylpropenyl)-1,4-
naphthoquinone (2g)







C 55.96; H 3.76; N 3.26%; found: C 55.92; H 3.74; N 




8.11 (dd, 1H, J 7.61, 
J 1.64 Hz), 8.08 (dd, 1H, J 7.61, J 1.45 Hz), 7.72 (td, 1H, 
J 7.61, J 1.45 Hz), 7.63 (td, 1H, J 7.61, J 1.64 Hz), 7.40 
(m, 1H), 6.90 (m, 3H), 5.89 (m, 1H), 1.44 (d, 3H, J 1.49 
Hz), 1.23 (d, 3H, J 1.28 Hz). 13C NMR (75 MHz, CDCl
3
): 
184.1, 182.9, 140.5, 140.1, 137.3, 136.1, 134.6, 133.1, 
132.4, 130.1, 126.9, 126.3, 124.3, 123.2, 118.1, 116.9, 
100.1, 87.1, 25.2, 20.5. IR (KBr) ν
max
/cm-1: 3331, 3069, 





(log ε 4.30), 456 (3.40). 
2-(4-Cyano-phenyl)amino-3-(2-methylpropenyl)-1,4-
naphthoquinone (2h)









C 76.81; H 4.91; N 8.53%; found: C 76.79; H 4.87; N 8.50%. 
1H NMR (300 MHz, CDCl
3
): d 8.14 (dd, 1H, J 1.59, J 7.46 
Hz), 8.12 (dd, 1H, J 1.49, J 7.46 Hz), 7.77 (td, 1H, J 7.46, J 
7.46, J 1.49 Hz), 7.70 (td, 1H, J 7.46 Hz, J 7.46, J 1.59 Hz), 
7.52 (br d, 2H, J 8.58 Hz), 6.90 (br d, 2H, J 8.58 Hz), 6.03 
(m, 1H), 1.50 (d, 3H, J 1.48 Hz), 1.24 (d, 3H, J 1.27 Hz). 13C 
NMR (75 MHz, CDCl
3
): 184.4, 182.8, 141.9, 141.4, 138.6, 
135.1, 133.2, 132.0, 130.7, 127.0, 126.7, 121.7, 120.3, 119.2, 
118.8, 106.1, 100.3, 25.9, 21.0. IR (KBr) ν
max
/cm-1: 3282, 





/nm: 290 (log ε 4.19), 471 (3.48).
2-(3-Cyano-phenyl)amino-3-(2-methylpropenyl)-1,4-
naphthoquinone (2i)









C 76.81; H 4.91; N 8.53%; found: C 76.77; H 5.01; N 




8.15 (ddd, 1H, J 
5.25 Hz, J 1.60 Hz, J 0.46 Hz), 8.12 (ddd, 1H, J 5.25 Hz, 
J 1.60 Hz, J 0.46 Hz), 7.76 (td, 1H, J 5.25, J 5.25, J 1.60 
Hz), 7.69 (td, 1H, J 5.25, J 5.25, J 1.60 Hz), 7.34 (m, 2H), 
7.11 (m, 2H), 5.95 (m, 1H), 1.47 (d, 3H, J 1.37 Hz), 1.25 
(d, 3H, J 1.14 Hz). 13C NMR (75 MHz, CDCl
3
): 183.7, 
182.4, 140.8, 138.7, 138.2, 134.7, 132.8, 132.7, 130.2, 
128.3, 126.7, 126.5, 126.2, 126.0, 124.9, 118.4, 118.1, 
111.5, 25.3, 20.5). IR (KBr) ν
max
/cm-1: 3281, 3081, 2970, 





284 (log ε 4.02), 475 (3.19).
2-(4-Nitro-phenyl)amino-3-(2-methylpropenyl)-1,4-
naphthoquinone (2j)









C 68.96; H 4.63; N 8.04%; found: C 68.86; H 4.55; N 
8.03%. 1H NMR (300 MHz, CDCl
3
): d 8.14 (m, 4H), 7.87 
(br s, 1H), 7.78 (td, 1H J 7.59, J 7.59, J 1.47 Hz), 7.71 (td, 
1H, J 7.59, J 1.57 Hz), 6.91 (br d, 2H, J 9.08 Hz), 6.08 
(m, 1H), 1.27 (d, 3H, J 1.17 Hz), 1.53 (d, 3H, J 1.43 Hz). 
13C NMR (75 MHz, CDCl
3
): 184.0, 182.3, 143.4, 142.4, 
141.4, 138.0, 134.7, 132.7, 132.9, 130.7, 126.6, 123.6, 
120.4, 120.8, 118.3, 99.8, 25.6, 20.7. IR (KBr) ν
max
/cm-1: 





/nm: 281 (log ε 4.37), 469 (3.63).
2-(3-Nitro-phenyl)amino-3-(2-methylpropenyl)-1,4-
naphthoquinone (2k)









C 68.96; H 4.63; N 8.04%; found: C 68.49; H 4.66; N 




8.15 (ddd, 1H, J 
7.57, J 1.46, J 0.49 Hz), 8.13 (ddd, 1H, J 7.57, J 1.46, J 
0.49 Hz), 7.91 (ddd, 1H, J 8.06, J 1.93, J 0.98 Hz), 7.82 
(br s, 1H), 7.77 (td, 1H, J 7.57, J 7.57, J 1.46 Hz), 7.69 
(td, 1H, J 7.57, J 1.46 Hz), 7.67 (br s, 1H), 7.40 (br t, 1H, 
J 8.06 Hz), 7.21 (dd, 1H, J 8.06, J 1.95 Hz), 6.01 (m, 1H), 
1.43 (d, 3H, J 1.46 Hz), 1.24 (d, 3H, J 0.98 Hz). 13C NMR 
(75 MHz, CDCl
3
): 183.8, 182.4, 147.3, 141.1, 138.6, 134.7, 
132.8, 132.7, 130.2, 128.1, 127.1, 126.5, 126.2, 118.7, 
118.4, 117.9, 116.3, 25.4, 20.6). IR (KBr) ν
max
/cm-1: 3279, 





/nm: 275 (log ε 4.39), 470 (3.59).
X-ray crystallography 
The X-ray diffraction data for 2b were collected at 
295 K from a Enraf-Nonius Kappa-CCD27 diffractometer 
with graphite monochromatized Mo Ka radiation. The cell 
parameters were obtained and refined using PHICHI28 and 
EvalCCD29 programs. Intensities for (1) were corrected by 
Lorentz polarization and absorption with the SADABS30 
program. The structure was solved by SHELXS-97 Direct 
Methods,29 and refined with SHELXL-97,32 contained 
within the WinGX-32 crystallography program.33 The 
positional parameters of the H atoms bonded to C atoms in 
the phenyl rings were obtained geometrically, with the C-H 
distances fixed in 0.93Å for Csp2, and refined as riding on 
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their respective C atoms, with U
iso
(H) = 1.2Ueq(Csp2). H 
atoms bonded to C atoms in the methyl group were located 
geometrically and with the C-H distances fixed at 0.96Å 
for Csp3 and with U
iso
(H) = 1.5Ueq(Csp3). The positional 
parameters of atom H1 bonded to N1 was obtained from a 
Fourier difference map and refined freely with an isotropic 
displacement parameter; the distance for N1-H1 is 0.87(2). 
X-ray data are listed in Table 3 and ORTEP-334 for Windows 
was used to draw the Figures. 
Antitumor assays
The compounds (1-5 mg mL-1) were tested for 
cytotoxic activity against four cancer cell lines: SF-295 
(Central Nervous System), HCT-8 (colon), MDAMB-435 
(breast) and HL-60 (human leukemia). All cell lines were 
maintained in RPMI 1640 medium supplemented with 
10% fetal bovine serum, 2 mmol L-1 glutamine, 100 U mL-1 
penicillin, and 100 mg mL-1 streptomycin at 37 oC with 5% 
CO
2
. Each compound was dissolved in DMSO and diluted 
with water to obtain a concentration of 1 mg mL-1. They 
were incubated with the cells for 72 h. The negative control 
received the same amount of DMSO (0.5% in the highest 
concentration). Doxorubicin (0.1-0.58 mg mL-1) was used 
as a positive control. The cell viability was determined by 
reduction of the yellow dye 3-(4,5-dimethyl-2-thiazol)-2,5-
phenyl-2H-tetrazolium bromide (MTT) to a blue formazan 
product as described by Mosmann.35
Conclusions
The eleven novel aminonaphthoquinones 2a-k, obtained 
from methoxy-nor-lapachol and various arylamines, 
were synthesized in good yields and showed interesting 
electrochemical behavior due to the nature of the substituents 
in the phenylamino ring, presenting a good correlation with 
Hammett parameter, which confirms that the reaction with 
electron-donor or electron-attracting groups follow a single 
mechanism. Unfortunately, because the arylamine derivatives 
of nor-lapachol were not active against the tested tumor 
cells, correlation between structure, electrochemical data 
and antitumor activity could not be attempted. 
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1. Theoretical Calculations
Starting from the experimental structure for 2b (4-Me), 
the geometries of 2a-2e and 2h-2i were fully optimized 
with the B3LYP/6-31G(d) method. Energies and molecular 
properties were obtained from a single-point calculation 
using the 6-311+G(2d,p) basis set and the B3LYP 
functional. To confirm that the most stable conformation in 
the gas-phase is similar to that found in the solid state the 
geometry of an alternative conformation for 2b, with the 
2-methyl-propenyl group bonded to the position 3 of the 
naphthoquinone ring rotated by 180o was also optimized. 
This alternative conformation was found 0.4 kcal mol-1 
less stable than the solid state conformation. The barrier 
for conversion between the two conformers calculated at 
the 6-31G(d) level is 5.5 kcal mol-1.
The orientation of the 2-phenylene ring is stabilized 
by an intramolecular hydrogen bond with one carbonyl 
group of the naphthoquinone ring and was, therefore, not 
further investigated. NMR absolute chemical shifts were 
calculated using the GIAO (Gauge Independent Atomic 
Orbital) method with the B3LYP/6-311+G(2d,p) approach 
on the B3LYP/6-31G(d) optimized geometry. Absolute 
energies and GIAO nuclear magnetic shielding tensors for 
H(18) are given in Table S1. Interestingly, the d
H18
 value for 
the alternative conformation (with the 2-methyl-propenyl 
group rotated by 180o, entry 2b-4 in Table S1) is 1.67 ppm 
shifted highfield as compared to the same hydrogen in the 
most stable conformation. Calculation for 2b on a geometry 
with the methoxy group rotated by 90o (entry 2b-2 in Table 
S1) yielded essentially the same d
H18
 value as that obtained 
for the most stable conformation. To verify the effect of 
the solvent on the chemical shifts some calculations were 
repeated with the solvent chloroform, using the CPCM 
approach. These calculations revealed that the solvent has 
only marginal influence on the relative chemical shifts.
The electronic spectra were calculated using the TD 
(Time Dependent) methodology available in Gaussian. 
The PBE1PBE functional together with the 6-311+G(2d,p) 
basis set was employed. All calculations were carried out 
with the G03W package of molecular orbital calculation.
2. Crystallographic Data
2.1. Computing details
Data collection: COLLECT (Nonius, 1998); cell 
refinement: PHICHI (Duisenberg, 2000); data reduction: 
EVALCCD (Duisenberg, 2003); program(s) used to solve 
structure: SHELXS97 (Sheldrick, 1997); program(s) used 
to refine structure: SHELXL97 (Sheldrick, 1997); molecular 
graphics: ORTEP-3 for Windows (Farrugia, 1997); software 
used to prepare material for publication: WinGX publication 
routines (Farrugia, 1999).
2.2. Experiment X-ray diffraction 
The X-ray diffraction data for (2b) were collected at 
295 K from a Enraf-Nonius Kappa-CCD diffractometer 
with graphite-monochromatized Mo Ka radiation. The cell 
parameters were obtained and refined using PHICHI and 
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EvalCCD programs. Intensities for (2b) were corrected 
by Lorentz polarization and absorption with the SADABS 
program. The structure was solved by SHELXS-97 Direct 
Methods, and refined with SHELXL-97, contained within 
the WinGX-32 crystallography program. The positional 
parameters of the H atoms bonded to C atoms in the 
phenyl rings were obtained geometrically, with the C-H 
distances fixed in 0.93Å for Csp2, and refined as riding on 
their respective C atoms, with U
iso
(H) = 1.2Ueq(Csp2). H 
atoms bonded to C atoms in the methyl group were located 
geometrically and with the C-H distances fixed at 0.96Å 
for Csp3 and with U
iso
(H) = 1.5Ueq(Csp3). The positional 
parameters of H(1) bonded to N(1) was obtained from a 
Fourier difference map and refined freely with an isotropic 
displacement parameter; the distance for N(1)-H(1) is 
0.87(2). X-ray data are listed in Table S2.
Crystallographic data for the structural analysis of 
compound 2b have been deposited with the Cambridge 
Crystallographic Data Center, CCDC 734112. Copies of 
this information may be obtained free of charge from The 
Director, CCDC, 12 Union Road, Cambridge, CB2 1EZ, UK 
(fax: +44 1233336 033; e-mail: deposit@ccdc.cam.ac.uk).
The packing of 2b involves molecules that interact intra- 
and intermolecularly through classical and non-classic 
hydrogen bonds, forming a 1D infinite network along the 
[100] crystallographic direction (Figures S2 and S3). The 
naphthoquinone carbonyl O1i interacts via classical and 
non-classic hydrogen bonds with H(1) to N(1) (imine 
group) and with H(12) to C(12) [C(11)-C(16) phenyl 
ring] of a neighboring molecule forming a six membered 
ring [symmetry code: i = x-1, y, z]. In addition the other 
carbonyl group interacts via O2ii with H(5) to C(5) forming 
a ten membered ring in association with N(1)-H(1)…O(1). 
The H-bond geometric parameters are listed in Table S4. 
Table S5 gathers the atomic coordinates and equivalent 
isotropic displacement parameters.
Table S1. Absolute energies (Hartree) and GIAO nuclear magnetic shielding tensors (ppm) for compounds 2a-2e and 2h-2i. All calculations were carried 
out on a optimized B3LYP/6-31G(d) geometry
Absolute energies / hartree GIAO nuclear magnetic shielding tensors / ppm
Derivative B3LYP/6-31+G(d,p) B3LYP/6-311+G(2d,p) B3LYP/6-31+G(d,p)a B3LYP/6-311+G(2d,p)b
2a (H) -977.62466 - 24.64 -
2b-1 (4-OMe) -1092.15228 -1092.40283 24.64 24.97
2b-2 (4-OMe)c -1092.14589 - 24.67 -
2b-3 (4-OMe)d -1092.16808 - 24.64 -
2b-4 (4-OMe)e -1092.16687 - 26.31 -
2l (3-OMe) -1092.15346 -1092.40399 24.62 24.89
2c (4-Fc) -2627.17389 -2627.55599 24.66 24.79
2m (3-Fc) - -2627.55562 - 24.85
2d (4-Me) -1016.94536 -1017.17288 24.60 24.86
2e (3-Me) - -1017.17322 - 24.81
2h-1 (4-CN) -1069.87032 -1070.11410 24.50 24.79
2h-2 (4-CN)d -1069.89020 - 24.46 -
2i-1 (3-CN) -1069.86851 -1070.11232 24.54 24.75
2i-2 (3-CN)d -1069.88800 - 24.49 -
aAt this level, the absolute GIAO nuclear magnetic shielding of TMS is 32.09 ppm. bAt this level, the absolute GIAO nuclear magnetic shielding of TMS 
is 31.82 ppm. c Conformation with the methoxy group rotated by 90o. dCalculation with inclusion of solvent (CPCM, chloroform). The absolute GIAO 
nuclear magnetic shielding of TMS at this level is 31.63 ppm eAlternative conformation, with the 2-methyl-propenyl group rotated by 180o, including 
solvent effect (chloroform).
Figure S1. View of the ORTEP plot for 2b with labeled atoms and 50% 
probability ellipsoids. Figure S2. View of the intramolecular interaction.
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Figure S3. View of the self-assembly 1D by classical and non classical hydrogen bonds along the [100] crystallography direction. [Symmetry codes: 
(i) x-1, y, z; (ii) x+1, y, z].
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Table S4. Geometric parameters for non-classical H bonds for molecule 
(2b) (Å, °)
D-H···A D-H H···A D···A ∠D-H···A
N(1)—H(1) ···O(2) 0.87 (2) 2.18 (2) 2.620 (2) 111.2 (18)
N(1)—H(1) ···O(1)i 0.87 (2) 2.46 (2) 3.241 (2) 150.2 (18)
C(12)—H(12)···O(1)i 0.93 2.58 3.246 (2) 129
C(5)—H(5) ···O(2)ii 0.93 2.39 3.304 (2) 169
[Symmetry codes: (i) x-1, y, z; (ii) x+1, y, z]
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Table S5.  Atomic coordinates (× 104) and equivalent isotropic displacement parameters (A2 × 103) for (2b). U(eq) is defined as one third of the trace of 
the orthogonalized Uij tensor
x y z U(eq)
C(19) -974(2) -1627(2) 5732(2) 43(1)
C(20) -2387(3) -494(2) 5299(2) 52(1)
C(21)  -31(3) -2776(3) 4922(2) 70(1)
O(1) 1355(2) -120(2) 7804(1) 54(1)
O(2) -5563(2) 1227(2) 9030(1) 54(1)
C(2) -3178(2) -323(2) 8018(1) 33(1)
N(1) -4432(2) -1001(2) 7743(1) 38(1)
C(1) -3973(2) 916(2) 8784(1) 36(1)
C(9) -2800(2) 1709(2) 9233(1) 35(1)
O(3) -4254(2) -6772(1) 6747(1) 57(1)
C(10) -984(2) 1312(2) 8931(1) 35(1)
C(4) -239(2) 152(2) 8106(2) 36(1)
C(3) -1409(2) -604(2) 7634(1) 34(1)
x y z U(eq)
C(11) -4275(2) -2456(2) 7413(1) 34(1)
C(12) -5544(2) -2751(2) 6832(2) 40(1)
C(18) -559(2) -1641(2) 6757(2) 39(1)
C(16) -2999(2) -3610(2) 7728(2) 40(1)
C(8) -3498(2) 2840(2) 9955(2) 44(1)
C(14) -4310(2) -5325(2) 6920(2) 39(1)
C(15) -3008(2) -5025(2) 7473(2) 43(1)
C(5) 112(2) 2050(2) 9372(2) 44(1)
C(13) -5574(2) -4176(2) 6589(2) 43(1)
C(6) -601(3) 3166(2) 10106(2) 51(1)
C(7) -2398(3) 3565(2) 10390(2) 51(1)
C(17) -5788(3) -7133(2) 6440(2) 61(1)
3. 1H NMR and APT Spectra (CDCl3) of Compounds 2a-k
Figure S4. 1H NMR spectrum of 2-(phenyl)amino-3-(2-methylpropenyl)-1,4-naphthoquinone (2a).
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Figure S5. APT spectrum of 2-(phenyl)amino-3-(2-methylpropenyl)-1,4-naphthoquinone (2a).
Figure S6. 1H NMR spectrum of 2-(4-methoxy-phenyl)amino-3-(2-methylpropenyl)-1,4-naphthoquinone (2b).
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Figure S8. 1H NMR spectrum of 2-(4-ferrocenyl-phenyl)amino-3-(2-methylpropenyl)-1,4-naphthoquinone (2c).
Figure S7. APT spectrum of 2-(4-methoxy-phenyl)amino-3-(2-methylpropenyl)-1,4-naphthoquinone (2b).
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Figure S10. 1H NMR spectrum of 2-(4-methyl-phenyl)amino-3-(2-methylpropenyl)-1,4-naphthoquinone (2d).
Figure S9. APT spectrum of 2-(4-ferrocenyl-phenyl)amino-3-(2-methylpropenyl)-1,4-naphthoquinone (2c).
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Figure S12. 1H NMR spectrum of 2-(3-methylphenylene)amino-3-(2-methylpropenyl)-1,4-naphthoquinone (2e).
Figure S11. APT spectrum of 2-(4-methylphenyl)amino-3-(2-methylpropenyl)-1,4-naphthoquinone (2d).
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Figure S14. 1H NMR spectrum of 2-(4-iodo-phenyl)amino-3-(2-methylpropenyl)-1,4-naphthoquinone (2f).
Figure S13. APT spectrum of 2-(3-methyl-phenyl)amino-3-(2-methylpropenyl)-1,4-naphthoquinone (2e).
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Figure S16. 1H NMR spectrum of 2-(3-iodo-phenyl)amino-3-(2-methylpropenyl)-1,4-naphthoquinone (2g).
Figure S15. APT spectrum of 2-(4-iodo-phenyl)amino-3-(2-methylpropenyl)-1,4-naphthoquinone (2f).
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Figure S18. 1H NMR spectrum of 2-(4-ciano-phenyl)amino-3-(2-methylpropenyl)-1,4-naphthoquinone (2h).
Figure S17. APT spectrum of 2-(3-iodo-phenyl)amino-3-(2-methylpropenyl)-1,4-naphthoquinone (2g).
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Figure S20. 1H NMR spectrum of 2-(3-ciano-phenyl)amino-3-(2-methylpropenyl)-1,4-naphthoquinone (2i).
Figure S19. APT spectrum of 2-(4-ciano-phenyl)-3-(2-methylpropenyl)-1,4-naphthoquinone (2h).
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Figure S22. 1H NMR spectrum of 2-(4-nitro-phenylene)-3-(2-methylpropenyl)-1,4-naphthoquinone (2j).
Figure S21. APT spectrum of 2-(3-ciano-phenyl)amino-3-(2-methylpropenyl)-1,4-naphthoquinone (2i).
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Figure S24. 1H NMR spectrum of 2-(3-nitro-phenyl)amino-3-(2-methylpropenyl)-1,4-naphthoquinone (2k).
Figure S23. APT spectrum of 2-(4-nitro-phenyl)amino-3-(2-methylpropenyl)-1,4-naphthoquinone (2j).
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Figure S25. APT spectrum of 2-(3-nitro-phenyl)amino-3-(2-methylpropenyl)-1,4-naphthoquinone (2k).
Figure S26. VT 1H NMR spectra of compound 2a (range: 25oC to -90 oC) in CD2Cl2.
4. Variable Temperature 1H NMR Spectra of Compound 2a
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4. Cyclic Voltammograms (100mV) of Compounds 2a-k
Figure S27. CV of 2-(phenyl)amino-3-(2-methylpropenyl)-1,4-
naphthoquinone (2a).
Figure S28. CV of 2-(4-methoxy-phenyl)amino-3-(2-methylpropenyl)-
1,4-naphthoquinone (2b).
Figure S29.  CV of 2-(4-ferrocenyl-phenyl)amino-3-(2-methylpropenyl)-
1,4-naphthoquinone (2c).
Figure S30. CV of 2-(4-methyl-phenyl)amino-3-(2-methylpropenyl)-
1,4-naphthoquinone (2d). 
Figure S31. CV of 2-(3-methyl-phenyl)amino-3-(2-methylpropenyl)-
1,4-naphthoquinone (2e).
Figure S32. CV of 2-(4-iodo-phenyl)amino-3-(2-methylpropenyl)-1,4-
naphthoquinone (2f).
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Figure S33. CV of 2-(3-iodo-phenyl)amino-3-(2-methylpropenyl)-1,4-
naphthoquinone (2g).
Figure S34. CV of 2-(4-ciano-phenyl)amino-3-(2-methylpropenyl)-1,4-
naphthoquinone (2h).
Figure S35. CV of 2-(3-ciano-phenyl)amino-3-(2-methylpropenyl)-1,4-
naphthoquinone (2i).
Figure S36. CV of 2-(4-nitro-phenyl)amino-3-(2-methylpropenyl)-1,4-
naphthoquinone (2j).
Figure S37. CV of 2-(3-nitro-phenyl)amino-3-(2-methylpropenyl)-1,4-
naphthoquinone (2k).
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5. Antitumor Assays 
The antitumor screening of compounds 2a-k was 
carried out against three cancer cell lines: SF-295 (central 
nervous system), HCT-8 (colon), MDAMB-435 (breast) 
through an MTT assayref and the results are summarized 
in Table S6.
Table S6. Screening of the cytotoxic activity (growth inhibition %) of compounds 2a-k and 1
Compounds SF295 GI% HCT-8 GI% MDA-MB435 GI%
Average SD Average SD Average SD
2a (H) 68.20 4.80 73.75 1.68 54.20 5.00 
2b (4-OMe) -11.01 11.89 -2.95 13.01 24.54 9.15 
2c (4-Fc) 2.57 7.43 5.45 6.24 102.31 1.09 
2d (4-Me) 12.20 3.71 12.33 2.76 17.21 3.58 
2e (3-Me) 58.59 0.40 71.52 1.01 43.86 3.54 
2f (4-I) -4.93 23.88 10.29 2.13 -7.63 3.42 
2g (3-I) 2.49 2.20 15.92 4.49 25.14 13.42 
2h (4-CN) -5.79 0.56 2.65 0.84 10.72 0.93 
2i (3-CN) -12.56 2.48 6.73 6.36 -20.51 4.35 
2j (4-NO
2
) 8.78 0.90 17.00 1.44 -18.20 8.24 
2k (3-NO
2
) -7.40 4.20 17.03 2.02 4.01 7.68 
1 41.09 15.08 27.01 3.12 106.05 0.16 
DOX 96.19 0.63 94.85 3.99 95.38 2.23
DOX = positive control, doxorubicin.
